These data suggest a therapeutic usefulness of the RSK inhibitor PMD-026 to target MAPK pathway-hyperactivated melanoma cells irrespective of their mutational subgroup and either as monotherapy or in combination with MAPK pathway inhibitors. Here, RPS6KA1 is linked to melanoma.